Eli Lilly And Co LLY, Vir Biotechnology Inc VIR, and GlaxoSmithKline plc GSK have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-administered with VIR-7831 in low-risk adult patients with mild to moderate COVID-19.
- Results showed that bamlanivimab 700 mg co-administered with VIR-7831 500 mg demonstrated a 70% relative reduction in persistently high viral load at day seven compared to placebo, meeting the primary endpoint.
- Also, the treatment demonstrated a statistically significant reduction compared to placebo in the critical virologic secondary endpoints of mean change from baseline to days three, five, and seven in SARS-CoV-2 viral load.
- No events for the secondary endpoint of COVID-19 related hospitalization or death by day 29 in either study arm were reported.
- One patient (in the treatment arm) visited the emergency room for COVID-19 related symptoms.
- No serious adverse events were seen with the coadministration of bamlanivimab and VIR-7831.
- Last week, the FDA acting commissioner Janet Woodcock said that the U.S. government is not distributing Eli Lilly's bamlanivimab alone in California, Arizona, and Nevada amid prevalent COVID-19 virus variants.
- Price Action: LLY shares are down 0.28% at $184.8, and VIR shares are dow 1.03% at $51 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in